Comparing Tear Proteomics Profile in Dry Eye Disease pre-and Post-treatment With Low Level Light Therapy

NCT07329712 | Recruiting

• 1 other identifier: 2025-0870
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this research study is to understand the mechanism of action of low level light therapy and also potentially yield markers associated with good treatment response. Low-level light therapy is light-based treatment delivered through advance eye-light device. This therapy uses light energy to provide energy to the meibomian gland cells to slow down age-ing, improve tear stability and reduce inflammation.

Conditions

Dry Eye; Meibomian Gland Dysfunction (Disorder)

Keywords

Dry Eye; low level light therapy; Eyelight; Tears proteomics; tear cytokine; MGD

Outcome Measures

Primary Outcomes (1)

• Comparing tear proteomics profile in dry eye disease pre-and post-treatment with low level light therapy

  Aim 1: Tear proteomic profile of MGD patients with DED pre- and post-treatment with LLLT will be profiled Aim 2: Baseline tear cytokine levels will be measured using the novel Olink 500-plex technology in DED patients with MGD undergoing LLLT

  Baseline visit and Post Baseline visit 3 months (+3 weeks).

Study Arms (1)

Patients undergoing low level light therapy

Eligibility Criteria

• Age: 21 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patient undergoing low level light therapy that met the study inclusion and exclusion

You may qualify if:

• Must be eligible for, and have consented for low level light therapy
• Must not have presented to the clinic for an acute eye problem such as visual loss or painful eye
• Ability to give informed consent.
• Age more or equals to 21 years old.

You may not qualify if:

• Patients who are unable to or decline to give consent.
• Age less than 21 years old.
• Patients who presented to the clinic for an acute eye problem such as visual loss or painful eye.
• Patients not suitable for low level lighttherapy:
• Pregnant
• Fitted with pacemakers, metal, electrical, acoustic prosthetics
• Epilepsy, cardiac rhythm or frequency disorders
• Fever, thrombophlebitis or acute phlebitis of the legs, large-sized varicose veins, or venous surgery within 2 months
• Uncontrolled hypertension or severe diabetes
• Open wounds on eyelid or skin
• Evolving cancer or hepatitis
• Blood anticoagulant or coagulation defect

Sponsors & Collaborators

• Singapore National Eye Centre: lead

Study Sites (1)

Singapore Eye Research Insititute

Singapore, Singapore

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Tears Sample (Schirmers Test)

MeSH Terms

Conditions

Dry Eye Syndromes; Meibomian Gland Dysfunction

Condition Hierarchy (Ancestors)

Lacrimal Apparatus Diseases; Eye Diseases; Eyelid Diseases

Study Officials

• Louis Tong, PhD

  Singapore Eye Research Institute

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Louis Tong Tong, PhD

CONTACT

65767200; louis.tong.h.t@singhealth.com.sg

Jiayi Lee, MSc

CONTACT

lee.jiayi1@singhealth.com.sg

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinician-Scientist, Senior Consultant

Study Record Dates

• First Submitted: December 21, 2025
• First Posted: January 9, 2026
• Study Start: November 5, 2025
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2027
• Last Updated: January 9, 2026

Record last verified: 2025-11

Locations

SG (1)